- **Full Title:** Risk of Heart Failure among Individuals with Metabolic Syndrome Components
- **Corresponding Author**:
- Rajan Lamichhane, PhD
- Assistant Professor
- Department of Clinical and Translational Sciences (DCTS)
- Joan C. Edwards School of Medicine
- Marshall University1600 Medical Center Drive, Room 256
- Huntington, WV 25701
- ☏ 304-691-8648
- lamichhaner@marshall.edu

#### **Co-authors:**



## **Abstract**

 Metabolic dysfunction of metabolic syndromes (MetS) has been widely reported to be a significant risk factor for heart failure (HF). While this interaction is well studied, what combinations of MetS factors pose the greatest risk for HF are not well defined. We hypothesize that some components of MetS are of higher risk of HF compared to others. We explored the relationship between the independent components of MetS and their combinatory effect on the risk of HF. All metabolic syndrome components except hypertriglyceridemia were significant individually (P-value<0.001), while hypertension (HTN) and diabetes or insulin resistance (IR) had the higher risk of developing heart failure when taken collectively. The odds of heart failure among the individuals who had HTN and IR was 7.7 times those who didn't have any MetS 43 components. We observed the additive effect of number of metabolic components on HF, for the individuals who had only one MetS symptom, the odd of HF was 5.4 time compared to those who didn't have any of MetS symptoms. Similarly, these odds of HF were 6.4 and 7.4 times for those who had at least 2 or at least 3 symptoms respectively. Even though obesity is a significant risk factor for cardiovascular diseases, we found the protective effect of obesity on heart failure, which is an interesting result and needs further investigation.

**Keywords:** Retrospective case-control study, metabolic syndrome, heart failure, obesity,

hypertension, insulin resistance, risk analysis

## **Non-standard Abbreviations and Acronyms**

- CVD CardioVascular Disease
- MI Myocardinal Infaction
- MetS Metabolic Syndrome
- IR- Insulin Resistance
- HTN Hypertension
- HG HypertriGlyceridemia
- HDL Low High-Density Lipoprotein
- HF Heart Failure
- BMI Body Mass Index
- IHD Family history of Ischemic Heart Disease
- CAD History of Coronary Artery Disease
- OR Odds Ratio
- AR Attributable Risk
- HFpEF Heart Failure with preserved Ejection Fraction
- HFrEF Heart Failure with reduced Ejection Fraction
- HbA1c Hemoglobin A1c

#### 71 **Introduction**

72 Cardiovascular disease (CVD) is the leading cause of death in the United States  $\frac{1}{2}$  and CVD is the 73 most common cause of myocardial infarction (MI). An MI occurs every 40 seconds; every year, 74 about 805,000 people in the United States have an MI<sup>2</sup> accounting for 13.4% of all registered 75 deaths in 2018<sup>1</sup>. 76 Metabolic Syndrome (MetS) is associated with numerous adverse health outcomes including 77 CVD <sup>3-9</sup>. MetS is comprised of five components—insulin resistance (IR), hypertension (HTN), 78 hypertriglyceridemia (HG), low high-density lipoprotein cholesterol (HDL), and obesity  $10$ . 79 Several research studies focused on the relationship between MetS and Heart Failure (HF) 11-13, 80 but limited work shows the association between MetS factors and HF. The components of MetS 81 have been linked to an increased risk for HF <sup>14-16</sup>; however, their interactions are not defined. It

82 is not common to find individuals with only a single component of MetS, rather, they present

83 together as a constellation often unique to the individual. It is therefore important to study the

84 simultaneous effect of these components on HF as they overlap among the same group of

85 people. Understanding the risk of HF among each of the MetS components could help direct

86 screening and treatment. In our study, we intend to identify the MetS components and their

87 respective combinations that create the highest risk of developing HF.

88 Our study is focused on the Appalachian population as this region has a disproportionately 89 higher incidence of HF compared to the rest of the United States <sup>17</sup>. Also, Appalachia performs 90 worse than the nation in several health indicators. According to the Appalachian Regional



 This study of the rural Appalachian population is important to understand the mechanism of HF among this medically underserved population. The presence of comorbidities, like smoking 95 and obesity, significantly affects the long-term morbidity and mortality of patients with HF  $^{20}$ . Population studies have shown that metabolic syndrome increases the risk of developing HF and this effect is mediated by insulin resistance. However, obesity is a key component in metabolic syndrome and a customary partner of insulin resistance because it is protective in patients with established HF, although insulin resistance confers an increased risk of dying from HF. Obesity, a key element of MetS, is often present alongside insulin resistance. In 101 patients with HF, obesity can offer a degree of protection, although insulin resistance is associated with an increased risk of mortality from HF. This phenomenon is called the "obesity 103 paradox" accounting for the complexity of the relationship between HF and MetS  $^{21}$ . This paradoxical relationship between MetS and HF should further be investigated to understand the relationship between MetS and HF. Our study aims to investigate this complex relationship between MetS and HF, further breaking down into different individual components of MetS. It is important to understand the role of each of the MetS components to develop customized strategies for HF prevention and treatment. We explore the relationship between MetS and its components with HF to determine which individuals will have a greater need for preventive or 110 therapeutic measures aimed at reducing the risk of HF. Recommendations from this study could help in developing strategies and guidelines based on MetS components to alleviate the burden of HF.

# **Study Design and Methods**

# **Data sources and study design**





This study was approved by Marshall University IRB (FWA 00002704).

#### **Statistical Approach**

In this retrospective case-control study, we implemented the nearest neighbor propensity score

- method to match the 121 HF cases with 363 control subjects that did not have HF. The cases
- were matched by age, gender, and heart disease history.

 The descriptive summaries were presented as mean ± SE for the continuous variables and 160 frequency (percent)  $\pm$  SE for the categorical variables. The odds of HF among individuals who met the criteria for MetS and other components were individually calculated. We investigated how MetS components—IR, low HDL, HTN, and HG—individually and simultaneously impacted the risk of HF by using logistic regression models after adjusting for other risk factors (covariates) of HF. This ensures which components of MetS contributed to the higher risk of HF when taken collectively. Once the important components were identified, we compared the risk of HF among the individuals who had those components and their combinations against the 167 other components. In our analyses, HF status was the outcome variable, while MetS status- comprising HTN, HG, HDL, and combinations of previously identified significant components, each taken separately—served as the primary predictor variables. These results were further validated by running logistic regressions of HF on the number of MetS components to assess for an incremental increase in risk upon adding components. In the analyses, we controlled the other variables: age, gender, history of tobacco and alcohol use, history of CAD, and inherited syndromes.

174 All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). The 175 results were considered statistically significant when the p-values were less than 0.05.

#### 176 **Results**







error

188



**Table 2a:** Logistic regression analysis of Heart Failure on different Metabolic Syndrome components





NA- Not enough samples to evaluate







**only**



212

213 We justified the above findings by investigating the effect of metabolic syndrome components

214 on HF. Table 3 shows the additive effect of metabolic syndrome symptoms on HF.



## **Table 3:** Logistic regression of HF on total number of MetS components **Heart Failure**

\*\* Not enough data to evaluate

215

 The odds of HF had increased as the number of MetS components increased. The odds of HF with at least one MetS components was 5.4 times (*P* value=0.023) compared to individuals with no components. Similarly, individuals with at least 2 and at least 3 MetS components had odds of HF was 6.4 and 7.4 times, respectively, compared to those with no reported MetS. There were  few individuals with at least 4 components; among these individuals, 79% of the risk of HF was solely attributable to at least 4 MetS components.

#### **Discussion**

 We explored the relationship between MetS and its components with HF which could provide personalized HF screening, preventive, and treatment options for patients with HF. Overall, insulin resistance and hypertension were the most important components of MetS that could 226 collectively increase the risk of HF. MetS and its components—IR, HTN, and obesity—were significant risk factors for HF. Most patients had multiple components present, so the risk of individual effects could be confounding. Instead, we collectively analyzed the components: the 229 patients with IR and HTN had a higher risk compared to those with at least one other component—HG, obesity, or HTN. There is an increased risk of developing HF as the number of metabolic components increases.

 Our findings were in line with past research studies while also generating some novel results. Several studies established the relationship between MetS and HF and indicated the increased 234 HF risk among patients with MetS  $22-23$ . Our results also identified MetS as an important risk factor for HF. We identified HTN as the most significant contributing factor to HF risk, which 236 can be correlated to a physiologic basis as follows. Hypertension increases left ventricular 237 afterload and peripheral vascular resistance, leading to pressure and volume-mediated left 238 ventricle remodeling<sup>24</sup>. This remodeling results in diastolic dysfunction, which is often the first sign of increased load. Chronic hypertension, involving both pressure and volume overloads, can lead to either concentric or eccentric left ventricular hypertrophy, associated with heart

 failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF), 242 respectively .

 Diabetes is another important risk factor for HF. IR, the primary endocrine dysfunction of diabetes, disrupts glucose uptake and utilization by cardiomyocytes, leading to energy 245 deficits and impaired contractility<sup>25</sup>. This metabolic inflexibility generates reactive oxygen 246 species and induces mitochondrial dysfunction <sup>26</sup>. The pathophysiology of diabetes-associated HF involves several key mechanisms. Elevated hemoglobin A1c (HbA1c) levels are associated with an increased risk of HF. Hyperglycemia leads to the formation of advanced glycation end-249 products and the modification of proteins by β-N-acetylglucosamine, which can negatively 250 impact cardiac function <sup>27</sup>. Systemic inflammation observed in patients with diabetes likely contributes to cardiac complications. Autonomic dysfunction, disturbances in myocardial metabolism, cardiac remodeling, and poor perfusion are additional mechanisms of diabetes-253 induced  $HF^{28}$ .

 We were not able to isolate the effects of individual components due to the size limitations as these conditions were rarely observed as a single factor in our study population. However, we found that both HG and low HDL levels were independently associated with an increased risk of HF. Atherogenic dyslipidemia induced by HG and low HDL promotes endothelial dysfunction and atherosclerosis, compromising coronary blood flow and explaining our finding 259 pathologically .

 We observed a protective effect of obesity on HF. This may be due to our choice of measurement unit for obesity-BMI. Individuals with obesity often have preserved skeletal muscle mass and

 may have a better prognosis secondary to increased stroke volume and thus cardiac output compared with their counterparts who have reduced lean mass and lower stroke volume and cardiac output. Lean mass may play a major role in outcome differences seen in the HF population<sup>30</sup>. There are several strengths to our study. First, a few studies investigated the relationship 267 between some of the MetS components (IR, HTN) with HF but often did not adjust other risk factors. For most of our analyses, we adjusted for age, sex, BMI, tobacco use, alcohol consumption, family history of HF, and inherited syndromes shown to be related to HF. Second, it is unlikely to observe just a single component of MetS; it is important to study the simultaneous effect of these components on HF. We investigated the additive effects of metabolic components on HF and compared the risks of HF between patients with MetS and its components. Our study is the first to focus on studying the additive effect of individual metabolic syndrome components. Third, we performed the risk analysis based on the number of components (table 3) and found the increased odds of HF as the number of components increased, which is a novel finding. This study also has some limitations. First, the analysis was limited to mainly Central and North Central Appalachia, which may affect the generalizability of the study findings. However, the identified factors reflect the general pattern for the US population. Second, we could not include race, diet, and lifestyle information in the analyses even though they are significant risk factors 281 for HF 31,32. There was less racial diversity in the data due to the demographic structure of this 282 region, with more than 90% of the population being White<sup>33</sup>. Future research on HF should



#### **Acknowledgment**

- We acknowledge the Translational Sciences Core of COBRE/ACCORD, Clinical, and
- Translational Sciences Department, Joan C Edwards School of Medicine, Marshall University for

analytics support.

#### **References**

- 1. National Center for Health Statistics. Multiple Cause of Death 2018–2021 on CDC WONDER Database. Accessed February 2, 2024.
- 2. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. *Circulation*. 2023;147:e93–e621.
- 3. Virani SS, Alonso A, Benjamin EJ, et al. On behalf of the American Heart Association
- Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics
- Subcommittee. Heart Disease and Stroke Statistics—2020 Update: A Report From the



20. Cardarelli K, Westneat S, Dunfee M, May B, Schoenberg N, Browning S. Persistent

- disparities in smoking among rural Appalachians: Evidence from the Mountain Air Project. *BMC Public Health*. 2021;21(1), 270. https://doi.org/10.1186/s12889-021-10334-6 21. Herath J, & Brown, C. (2013). An Analysis of Adult Obesity and Hypertension in Appalachia. *Global Journal of Health Science.* 2013;5(3), 127–138. https://doi.org/10.5539/gjhs.v5n3p127. 22. Gargiulo P, Marsico F, Renga F, et al. The metabolic syndrome in heart failure: insights to specific mechanisms. *Heart Fail Rev.* 2020 Jan;25(1):1-7. doi: 10.1007/s10741-019-09838-6. 23. Arcopinto M, Schiavo A, Salzano A, et al. Metabolic Syndrome in Heart Failure: Friend or Foe? *Heart Fail Clin*. 2019 Jul;15(3):349-358. doi: 10.1016/j.hfc.2019.02.004. 24. Du Cailar G, Pasquie JL, Ribstein J, Mimran A. Left ventricular adaptation to hypertension and plasma renin activity. *J Hum Hypertens*. 2000;14:181–188. doi: 10.1038/sj.jhh.1000974. 25. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. *J Am Coll Cardiol*. 2006;48:89–96. doi: 10.1016/j.jacc.2006.01.077. 26. Liu M, Lv J, Pan Z, Wang D, Zhao L, Guo X. Mitochondrial dysfunction in heart failure and its therapeutic implications. *Frontiers in Cardiovascular Medicine*. 2022;9, 945142. https://doi.org/10.3389/fcvm.2022.945142 27. Prakoso D, De Blasio MJ, Qin C, et al. Phosphoinositide 3-kinase (p110 alpha) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. *Clin Sci (Lond*). 2017; 131: 1345. 28. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. *Pharmacol Ther*. 2014; 142: 375. 29. Grundy, SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. *Clinical Cornerstone*. 2006;8 Suppl 1, S21-27. https://doi.org/10.1016/s1098-
- 3597(06)80005-0
- 30. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. *Circulation*. 1999; 100: 813.
- 31. Billingsley HE, Hummel SL, Carbone S. The role of diet and nutrition in heart failure: A state-of-the-art narrative review. *Prog Cardiovasc Dis*. 2020 Sep-Oct;63(5):538-551. doi: 10.1016/j.pcad.2020.08.004.
- 32. Larsson SC, Tektonidis TG, Gigante B, Akesson A, Wolk A. Healthy Lifestyle and Risk of Heart Failure. *Circulation*. 2016; 9 (4).

## https://doi.org/10.1161/CIRCHEARTFAILURE.115.002855.

- 33. Pollard K, Jacobsen LA. The Appalachian region: A data overview from the 2008–2012 American community survey chartbook. *PRB*. 2014.
- 
- 
-